Çetin, D.; Bilgili, E.; Komaç, Ö.; Yetişken, M.; Güney, E.
Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study. Medicina 2025, 61, 1152.
https://doi.org/10.3390/medicina61071152
AMA Style
Çetin D, Bilgili E, Komaç Ö, Yetişken M, Güney E.
Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study. Medicina. 2025; 61(7):1152.
https://doi.org/10.3390/medicina61071152
Chicago/Turabian Style
Çetin, Deniz, Elif Bilgili, Ömer Komaç, Merve Yetişken, and Engin Güney.
2025. "Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study" Medicina 61, no. 7: 1152.
https://doi.org/10.3390/medicina61071152
APA Style
Çetin, D., Bilgili, E., Komaç, Ö., Yetişken, M., & Güney, E.
(2025). Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study. Medicina, 61(7), 1152.
https://doi.org/10.3390/medicina61071152